Creative Medical Technology Holdings, Inc. has agreed to buy 80% of BioDefense, Inc. shares.

Sep 25, 2026, 5:03 PM ETDealRead the original at SEC EDGAR

Neutral

CELZ now owns 80% of BioDefense, giving it control, but it paid $200,000 and 1,000,000 CELZ shares for the stake. The filing gives no details about BioDefense's business or results, and the seller is tied to CELZ's CEO, so the deal does not show whether the added control helps CELZ.

CELZ · Creative Medical Technology Holdings, Inc.

AI read · Neutral

The AI's read

Control gives CELZ a larger role in BioDefense, but the filing says nothing about BioDefense's products, sales, or finances. That leaves no clear way to judge what CELZ gained. CELZ also paid cash and issued shares to a company led by its own CEO, adding a cost and a relationship concern. The filing does not show whether the stake's value outweighs those costs.

Get alerts for CELZ

Follow Creative Medical Technology Holdings, Inc. (CELZ) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CELZ

Free on the App Store and Google Play, or on the web.